Figure 7.

Intranasal administration of anti-HMGB1 decreased the IL-23 production by lung CD11c⁺ APCs. (a) Administration of anti-HMGB1 downregulated the percentage of IL-23⁺ CD11c⁺ APCs in low-density lung cells. Representative results of the percentage of IL-23⁺ CD11c⁺ APCs in lung from mice in the control (A), asthma (B), control IgG-treated (C), and anti-HMGB1-treated groups (D) were analyzed using FACS. (b) Histogram showing the number of IL-23⁺ CD11c⁺ APCs in mice from the different groups. The values represent the means ± standard deviations (n = 5). *P < 0.05 and **P < 0.01 compared with the asthma group.